Bellerophon Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023019044 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.382M
YoY Change -61.28%
Cash & Equivalents $4.400M
Short-Term Investments
Other Short-Term Assets $597.0K
YoY Change -19.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.979M
YoY Change -58.71%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $4.979M
Total Long-Term Assets $0.00
Total Assets $4.979M
YoY Change -60.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $612.0K
YoY Change -59.87%
Accrued Expenses $644.0K
YoY Change -82.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.256M
YoY Change -75.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.256M
Total Long-Term Liabilities $0.00
Total Liabilities $1.256M
YoY Change -75.75%
SHAREHOLDERS EQUITY
Retained Earnings -$256.3M
YoY Change 3.75%
Common Stock $122.0K
YoY Change 28.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.723M
YoY Change
Total Liabilities & Shareholders Equity $4.979M
YoY Change -60.51%

Cashflow Statement

Concept 2023 Q4 2023 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001600132
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9645711
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12232648
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36845
dei Entity Registrant Name
EntityRegistrantName
Bellerophon Therapeutics, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3116175
dei Entity Address Address Line1
EntityAddressAddressLine1
20 Independence Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 402
dei Entity Address City Or Town
EntityAddressCityOrTown
Warren,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07059
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
574-4770
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
BLPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12232648
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4382000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6924000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
108000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
405000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
489000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
234000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
4979000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7563000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
184000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2023Q3 us-gaap Assets
Assets
4979000
CY2022Q4 us-gaap Assets
Assets
7935000
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
612000
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1230000
CY2023Q3 blph Accrued Research And Development
AccruedResearchAndDevelopment
336000
CY2022Q4 blph Accrued Research And Development
AccruedResearchAndDevelopment
2655000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
308000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1313000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
203000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1256000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5401000
CY2023Q3 us-gaap Liabilities
Liabilities
1256000
CY2022Q4 us-gaap Liabilities
Liabilities
5401000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12232648
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9645711
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
122000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
259916000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254516000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256315000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252078000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3723000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2534000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4979000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7935000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5640000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
544000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3750000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5992000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12646000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1626000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1366000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5599000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4653000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2170000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
5116000
us-gaap Operating Expenses
OperatingExpenses
11591000
us-gaap Operating Expenses
OperatingExpenses
17299000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2170000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5116000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5951000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17299000
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
140000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
140000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
297000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1921000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5069000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5514000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17232000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1277000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2417000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1921000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5069000
us-gaap Net Income Loss
NetIncomeLoss
-4237000
us-gaap Net Income Loss
NetIncomeLoss
-14815000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12232648
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9545451
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11614650
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9545451
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12232648
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9545451
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11614650
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9545451
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
5623000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1921000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3723000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2534000
us-gaap Net Income Loss
NetIncomeLoss
-4237000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1437000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
3545000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
418000
blph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3723000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
12280000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5069000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
217000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7428000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21619000
us-gaap Net Income Loss
NetIncomeLoss
-14815000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
624000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
7428000
us-gaap Profit Loss
ProfitLoss
-4237000
us-gaap Profit Loss
ProfitLoss
-14815000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
2000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
61000
us-gaap Share Based Compensation
ShareBasedCompensation
418000
us-gaap Share Based Compensation
ShareBasedCompensation
624000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
140000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
255000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-282000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-186000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
blph Increase Decrease In Accounts Payable Accrued Research And Development And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedResearchAndDevelopmentAndOtherLiabilities
-3961000
blph Increase Decrease In Accounts Payable Accrued Research And Development And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedResearchAndDevelopmentAndOtherLiabilities
430000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7987000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13418000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
140000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
140000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5008000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2839000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13418000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7329000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25139000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4490000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11721000
CY2023Q3 blph Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
3
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q3 blph Warrant Liability
WarrantLiability
0
CY2022Q4 blph Warrant Liability
WarrantLiability
0
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4400000
CY2023Q3 blph Number Of Operating Leases
NumberOfOperatingLeases
2
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
197000
us-gaap Operating Lease Payments
OperatingLeasePayments
205000
us-gaap Operating Lease Payments
OperatingLeasePayments
586000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
177000
us-gaap Operating Lease Cost
OperatingLeaseCost
185000
us-gaap Operating Lease Cost
OperatingLeaseCost
532000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0492
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2023Q3 blph Warrant Liability
WarrantLiability
0
CY2022Q4 blph Warrant Liability
WarrantLiability
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
217000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
624000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.109
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2023Q3 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1921000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-5069000
us-gaap Net Income Loss
NetIncomeLoss
-4237000
us-gaap Net Income Loss
NetIncomeLoss
-14815000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12232648
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9545451
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11614650
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9545451
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
12232648
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9545451
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
11614650
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9545451
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55

Files In Submission

Name View Source Status
blph-20230930_lab.xml Edgar Link unprocessable
0001558370-23-019044-index-headers.html Edgar Link pending
0001558370-23-019044-index.html Edgar Link pending
0001558370-23-019044.txt Edgar Link pending
0001558370-23-019044-xbrl.zip Edgar Link pending
blph-20230930.xsd Edgar Link pending
blph-20230930x10q.htm Edgar Link pending
blph-20230930xex10d1.htm Edgar Link pending
blph-20230930xex10d2.htm Edgar Link pending
blph-20230930xex10d3.htm Edgar Link pending
blph-20230930xex31d1.htm Edgar Link pending
blph-20230930xex32.htm Edgar Link pending
blph-20230930x10q_htm.xml Edgar Link completed
blph-20230930_cal.xml Edgar Link unprocessable
blph-20230930_def.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blph-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable